Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Randox Launches Three New ELISA Kits for the Detection of Z Drugs

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
ELISA kits for the detection of Zopiclone, Zaleplon and Zolpidem in urine and blood specimens.

Randox Toxicology has launched three new ELISA testing kits for the detection of sedative drugs Zopiclone, Zaleplon and Zolpidem.

These drugs behave in a similar ways to benzodiazepines, a psychoactive drug which was traditionally used for the treatment of anxiety or insomnia.

The Z drugs are found in prescription medications; Lunesta, Ambien and Sonata, however they should only be used for a short time period as extended use can lead to tolerance.

The misuse of Z drugs is widespread as a result of both dependence and recreational use. Despite medical advice, many people continue to take these drugs for longer periods than their intended usage; leading to a potential over-dose and hazardous consequences.

Incidents of unusual or inappropriate behaviour have been linked to misuse of Z drugs, were the patient had no memory of their actions.

Some users have reported sleepwalking, sleep driving, binge eating, and performing other daily tasks while asleep. These side effects are troubling in a society were sleeping pills have boomed in popularity.

Randox Toxicology has developed three ELISA kits for the detection of Z drugs in urine and blood specimens.

The Zolpidem ELISA offers an unbeatable Limit of Detection (LOD) of 0.4ng/ml in urine and 0.52ng/ml in blood.

The Zopiclone and Zaleplon ELISA kits are the first immunoassays available for the rapid detection of these drugs. Prior to this, the only way to detect Zopiclone and Zaleplon was with timely chromatographic analysis.

Randox Toxicology also provides an automated ELISA plate reader, capable of reading 96 wells in 30 seconds.

In addition to the Z drug ELISA kits, Randox Toxicology provide a multiplex Biochip Array which targets Zolpidem, Zopiclone, Zaleplon and their metabolites simultaneously from a single, undivided specimen.

The advanced multiplex method consolidates ELISA tests onto a small 9x9mm biochip; enhancing the ability for toxicologists to quickly detect these sedatives.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!